Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01517360 · ClinicalTrials.gov registry record · Phase 1
Pharmacological Approach to Improve the Outcome of Social Cognition Training
A Phase 1 study, sponsored by VA Greater Los Angeles Healthcare System.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01517360: Completed Phase 1 study, sponsored by VA Greater Los Angeles Healthcare System.
NCT01517360 is a Phase 1 study that has completed, run by VA Greater Los Angeles Healthcare System. The registered enrollment target is 27 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01517360, a Phase 1 study, has completed, sponsored by VA Greater Los Angeles Healthcare System.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study will evaluate whether oxytocin will facilitate the learning of social cognitive skills in schizophrenia patients who receive 12 sessions of Social Cognitive Skills Training (SCST). The primary hypothesis is that schizophrenia subjects who are treated with oxytocin will demonstrate greater improvements in a summary measure of social cognition than subjects treated with placebo over the course of SCST.
Primary Outcome
We will assess emotion management, emotion perception, social context processing/social perception, theory of mind, attributional bias, and empathic accuracy. The primary summary measure for each test will be mean-centered and standardized to create a Z-score that will be averaged to create a single composite score for social cognition, serving as the primary outcome measure. Parallel follow-up analyses will be conducted on individual components to determine which measures are most affected by t
Interventions
- OTHER Placebo
- DRUG Oxytocin
- BEHAVIORAL Social Cognitive Skills Training
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
What the finished NCT01517360 record still lists
NCT01517360 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01517360 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01517360 about?
NCT01517360 is a clinical study titled "Pharmacological Approach to Improve the Outcome of Social Cognition Training". This study will evaluate whether oxytocin will facilitate the learning of social cognitive skills in schizophrenia patients who receive 12 sessions of Social Cognitive Skills Training (SCST). The primary hypothesis is that schizophrenia subjects who are treated with oxytocin will demonstrate greater...
What is the current status of trial NCT01517360?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2012-01. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01517360?
The interventions under investigation include: Placebo (OTHER), Oxytocin (DRUG), Social Cognitive Skills Training (BEHAVIORAL).
Who is sponsoring clinical trial NCT01517360?
This trial is sponsored by VA Greater Los Angeles Healthcare System, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01517360's enrollment target sits among peer trials
27 1463rd of 2000 higher than 519 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia